Actinogen Medical (ASX: ACW)

Last close As at 20/12/2024

AUD0.03

0.00 (−3.85%)

Market capitalisation

AUD79m

Actinogen Medical is an ASX-listed Australian biotech developing its lead asset Xanamem, a specific and selective 11beta-HSD1 inhibitor designed to treat cognitive impairment (CI), which occurs in chronic neurodegenerative and neuropsychiatric diseases.

Latest Insights

View More
Actinogen Medical

Sector

Healthcare

Equity Analyst

Pooya Hemami

Analyst - Healthcare

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Dr Steven Gourlay

    CEO and MD

  • Michael Roberts

    Head of investor relations

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free